Evolus (EOLS) Earnings Date & Reports

Key Takeaways

• Evolus is scheduled to report second quarter 2026 results on August 5, 2026, after the U.S. market close.
• Wall Street consensus estimates project Q2 revenue of approximately $81.6 million to $83.6 million and a non-GAAP loss per share of roughly $0.04.
• The company enters this report with two consecutive quarters of positive Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a milestone that management expects to sustain through the full year.
• Investors will focus on Jeuveau unit growth trends, Evolysse filler revenue contributions, and any updates to the full-year 2026 guidance of $327 million to $337 million in total net revenue.
• Key product catalysts, including the recent European launch of the Estyme injectable hyaluronic acid gel line and the anticipated U.S. approval of Evolysse Sculpt, could shape post-earnings sentiment.
• The stock has pulled back roughly 13% over the past month, trading near $6.18, as broader market uncertainty and tariff-related concerns weigh on the aesthetic medicine sector.

Earnings Context and Why It Matters

Evolus (NASDAQ: EOLS), a global performance beauty company, is approaching a pivotal second quarter earnings report after delivering its second consecutive quarter of positive Adjusted EBITDA in Q1 2026 — a rare feat during what is historically its seasonally weakest revenue period. The report will test whether the company's dual-product strategy — pairing its flagship neurotoxin Jeuveau with the newer Evolysse line of injectable hyaluronic acid (HA) gels — can sustain double-digit annual revenue growth while keeping operating expenses in check. With the stock trading well below analyst price targets and the aesthetic injectables market navigating cautious consumer spending, this earnings release offers a critical read on demand resilience, margin trajectory, and the durability of Evolus's digitally enabled commercial platform.

Earnings Expectations

Analysts expect Evolus to report second quarter 2026 revenue in the range of approximately $81.6 million to $83.6 million, according to data compiled from multiple research consensus estimates. This would represent a meaningful increase from the $69.4 million reported in Q2 2025, when the company faced a difficult comparison that resulted in a wider-than-expected loss. On the bottom line, the consensus non-GAAP (adjusted) earnings per share estimate falls between a loss of $0.04 and a loss of $0.07, a substantial improvement from the loss of $0.25 per share (non-GAAP) reported in the same quarter last year.

In the prior quarter (Q1 2026), Evolus posted net revenue of $73.1 million — up 7% year-over-year — with $66.4 million from global toxin sales and $6.7 million from injectable HA gels. Adjusted EBITDA reached positive $0.6 million, compared to a loss of $5.5 million in Q1 2025. The company reaffirmed its full-year 2026 guidance: total net revenue between $327 million and $337 million, adjusted gross margin of 65.5% to 67.0%, non-GAAP operating expenses of $210 million to $216 million, and a low- to mid-single-digit Adjusted EBITDA margin. Management also indicated that Q2 U.S. Jeuveau net revenue growth would more than offset the Q1 headwind created by prior-year revenue deferral dynamics.

Beyond the headline numbers, investors will scrutinize several operating metrics: total purchasing account growth (which increased by nearly 500 in Q1), Evolus Rewards loyalty program membership (approaching 1.5 million), customer reorder rates (approximately 71%), and the pace of Evolysse adoption across U.S. accounts. Commentary on the 14% U.S. market share for Jeuveau and any updates regarding the newly announced 15% tariff on certain pharmaceutical imports from South Korea — effective September 29, 2026 — will also be closely watched.

AI Screener

As investors prepare for Evolus's upcoming earnings release, tools that streamline market analysis can offer a meaningful edge. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Rather than manually scanning charts and financial statements, users can quickly surface breakout candidates, emerging trends, and high-conviction trade ideas tailored to their strategy. For those monitoring the aesthetic medicine and performance beauty space, the AI Screener can help identify how Evolus compares to peers across fundamental and technical dimensions — all in one consolidated view.

Market Reaction and Investor Sentiment

Evolus shares enter the Q2 earnings event under modest pressure, having declined approximately 13% over the trailing month to around $6.18 as of late July 2026. The stock has traded within a wide 52-week range of $3.86 to $9.58, reflecting both the company's operational progress and lingering market skepticism about the sustainability of aesthetic injectable demand in a mixed consumer environment. Despite the recent slide, analyst sentiment remains notably bullish: seven covering analysts rate the stock a consensus Strong Buy with an average 12-month price target of $14.67 — more than double the current trading level. The disconnect between analyst targets and market price suggests that investors remain cautious, likely weighing tariff risks, competitive dynamics from larger players such as AbbVie's Botox, and the uncertain pace of Evolysse adoption against the company's improving profitability profile. A clean beat on both revenue and EPS, accompanied by maintained or raised guidance, could serve as a catalyst for the stock to close the gap with analyst expectations.

Forward Outlook and Key Factors to Monitor

Looking beyond the second quarter print, several interconnected themes will define Evolus's trajectory through the remainder of 2026 and into 2027.

The most immediate catalyst is the commercial execution of the Estyme injectable HA gel line in Europe, which launched in mid-May 2026. Management has guided that Evolysse and Estyme combined should contribute 10% to 12% of total company revenue this year, making the early uptake data a critical barometer for the portfolio diversification strategy. In parallel, the anticipated U.S. Food and Drug Administration (FDA) approval of Evolysse Sculpt — a mid-face filler — in the fourth quarter would open a new, high-value segment of the U.S. HA market where Evolus currently has no presence. CEO David Moatazedi has described Sculpt as the expected flagship of the HA product family.

On the risk side, the looming 15% tariff on pharmaceutical products imported from South Korea — including Jeuveau — represents a tangible margin headwind beginning in late September. Management has expressed confidence in its ability to mitigate or eliminate the impact, citing options such as inventory pre-stocking given Jeuveau's three-year shelf life, but clarity on a mitigation plan remains a key investor ask. The company's balance sheet position — $49.8 million in cash as of March 31, 2026, plus access to roughly $120 million in additional credit facilities — provides a cushion, though sustained cash consumption warrants monitoring.

Finally, Evolus's long-term framework — targeting $450 million to $500 million in total net revenue with Adjusted EBITDA margins of 13% to 15% by 2028 — sets a high bar that will require consistent execution across U.S. and international markets, continued account penetration above 60%, and successful integration of new products into the company's cash-pay, digitally enabled commercial model. Each quarter of demonstrated operating leverage brings that vision closer to reality, but the path remains conditional on consumer demand holding firm in an unpredictable macroeconomic climate.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations